Impact of the unplanned excision on the oncological outcomes of patients with soft tissue sarcomas: a single-center retrospective review of 490 patients
Acta Orthopaedica et Traumatologica Turcica · 11.08.2022 · 56 (4) · 272-277
DOI: 10.5152/j.aott.2022.21373 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Orthopaedica et Traumatologica Turcica, online erschienen am 11.08.2022. Verfasst von Andaç Celasun Alsina und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic and Trauma Surgery, Ege University, School of Medicine, İzmir, Turkey. Hauptthemen laut MEDLINE: Sarcoma, Soft Tissue Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
This study aimed to (1) compare the oncological results of patients who underwent re-excision after unplanned excision with those who underwent planned excision and (2) analyze the impact of local recurrences on oncological outcomes.
Methods
Patients with soft tissue sarcoma who had been treated in our center between 2000 and 2018 were retrospectively reviewed. Patients were divided into two groups: Group PE (Planned excision; n=345) and group UE (Unplanned excision; n=145). Two groups were compared in terms of local recurrence-free survival (LRFS), metastasis-free survival (MFS), and overall survival (OS). Local recurrences effects over MFS and OS were also analyzed.
Results
There were 26 (17.9%) local recurrences in the UE group and 30 (8.7%) local recurrences in the PE group (P=0.005). There was no difference in MFS and OS between study groups (P=0.278 and P=0.848, respectively). Five years MFS rates of UE and PE groups were 76.4% and 73.6%, and five-year OS rates of UE and PE groups were 70.3% and 73.9%, respectively (P=0.417, P=0.656). Patients with local recurrence had a 1.96 times higher risk of metastasis than patients without local recurrence (P=0.008). Patients with local recurrence had 1.65 times higher risk of mortality than patients without local recurrence (P=0.047).
Conclusion
Although local recurrence is much more common in the UE group, this outcome does not seem to affect MFS or OS. These results indicate that similar outcomes can be achieved if UE patients are referred and appropriately treated with wide re-resections. Level of Evidence: Level III, Therapeutic Study Cite this article as: Alsina AC, Sacchetti F, Kaya H, Yaman B, Tamsel İ, Sabah D. Impact of the unplanned excision on the oncological outcomes of patients with soft tissue sarcomas: a single-center retrospective review of 490 patients. Acta Orthop Traumatol Turc. 2022;56(4):272-277.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Orthopedic and Trauma Surgery, Ege University, School of Medicine, İzmir, Turkey.
- Department of Orthopedic and Trauma Surgery, University of Pisa, Italy.
- Department of Pathology, Ege University, School of Medicine, İzmir, Turkey.
Zitieren
APA
Alsina, A. C., Sacchetti, F., Kaya, H., Yaman, B., Tamsel, İ., & Sabah, D. (2022). Impact of the unplanned excision on the oncological outcomes of patients with soft tissue sarcomas: a single-center retrospective review of 490 patients. Acta Orthopaedica et Traumatologica Turcica, 56(4), 272-277. https://doi.org/10.5152/j.aott.2022.21373
Vancouver
Alsina AC, Sacchetti F, Kaya H, Yaman B, Tamsel İ, Sabah D. Impact of the unplanned excision on the oncological outcomes of patients with soft tissue sarcomas: a single-center retrospective review of 490 patients. Acta Orthopaedica et Traumatologica Turcica. 2022;56(4):272-277. doi:10.5152/j.aott.2022.21373
BibTeX
@article{Alsina2022,
author = {Alsina, Andaç Celasun and Sacchetti, Federico and Kaya, Hüseyin and Yaman, Banu and Tamsel, İpek and Sabah, Dündar},
title = {Impact of the unplanned excision on the oncological outcomes of patients with soft tissue sarcomas: a single-center retrospective review of 490 patients},
journal = {Acta Orthopaedica et Traumatologica Turcica},
year = {2022},
volume = {56},
number = {4},
pages = {272--277},
doi = {10.5152/j.aott.2022.21373}
}
EUVIMED